高级检索
当前位置: 首页 > 详情页

Role of prostaglandin E2 in macrophage polarization: Insights into atherosclerosis

文献详情

资源类型:
Pubmed体系:
机构: [1]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University.Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China.Institute of Chinese Medicine, Guangdong Pharmaceutical University.Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, Guangdong Province, China [2]Department of Endocrinology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi’an, Shaanxi Province, China
出处:
ISSN:

关键词: Prostaglandin E2 Atherosclerosis Macrophage polarization CREB NF-κB STAT

摘要:
Atherosclerosis, a trigger of cardiovascular disease, poses grave threats to human health. Although atherosclerosis depends on lipid accumulation and vascular wall inflammation, abnormal phenotypic regulation of macrophages is considered the pathological basis of atherosclerosis. Macrophage polarization mainly refers to the transformation of macrophages into pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes, which has recently become a much-discussed topic. Increasing evidence has shown that M2 macrophage polarization can alleviate atherosclerosis progression. PGE2 is a bioactive lipid that has been observed to be elevated in atherosclerosis and to play a pro-inflammatory role, yet recent studies have reported that PGE2 promotes anti-inflammatory M2 macrophage polarization and mitigates atherosclerosis progression. However, the mechanisms by which PGE2 acts remain unclear. This review summarizes current knowledge of PGE2 and macrophages in atherosclerosis. Additionally, we discuss potential PGE2 mechanisms of macrophage polarization, including CREB, NF-κB, and STAT signaling pathways, which may provide important therapeutic strategies based on targeting PGE2 pathways to modulate macrophage polarization for atherosclerosis treatment.Copyright © 2022 Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学
第一作者:
第一作者机构: [1]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University.Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China.Institute of Chinese Medicine, Guangdong Pharmaceutical University.Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, Guangdong Province, China
共同第一作者:
通讯作者:
通讯机构: [1]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University.Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China.Institute of Chinese Medicine, Guangdong Pharmaceutical University.Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou, Guangdong Province, China [2]Department of Endocrinology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi’an, Shaanxi Province, China [*1]280 Wai Huan Dong Road, Guangdong Pharmaceutical University, Guangzhou Higher Education Mega Center, Guangzhou 510006, China [*2]4 Xihuamen Road, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi’an 710003, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号